Noopept — reference
A synthetic dipeptide developed in Russia and marketed for cognitive effects.
Regulatory status
Not FDA-Approved. Not FDA-approved. The FDA has stated it does not meet the definition of a dietary ingredient, so US products marketed as supplements are outside that framework.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~0.1–1 hour (rapidly hydrolyzed to cycloprolylglycine). Small human/animal PK studies exist; parent compound clears fast.
This figure is tagged PK study in our evidence system. This figure comes from a published pharmacokinetic study rather than a label or registration trial. Sample sizes in such studies are often small and figures vary between them, so treat the number as a range rather than a constant. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Noopept FDA-approved?
What is the half-life of Noopept?
How reliable is that half-life figure?
What cautions are associated with Noopept?
Does Peptide Plug publish dosing for Noopept?
Does Peptide Plug sell Noopept?
Related tools
Free, no account required.